

■ **Ranbaxy, Daiichi Sankyo to Integrate Thailand Ops**

NEW DELHI Drug firm Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo will integrate their business operations in Thailand as part of strategy to maximise synergies. Both the companies intend to integrate their business operations in Thailand to leverage and maximise the synergies of hybrid business model, which is expected to commence business on April 1, 2013, Ranbaxy said in a statement on Wednesday. "The planned integration of operations will provide a strong foundation for future Daiichi Sankyo group expansion in Thailand," it added. The development would be mutually beneficial to Ranbaxy and Daiichi Sankyo as it is expected to enhance their competitiveness, the company said. As per the plan, Daiichi Sankyo and Ranbaxy would integrate the management of Daiichi Sankyo's subsidiary in Thailand, Daiichi Sankyo (Thailand) (DSTH) and Ranbaxy's Thailand subsidiary, Ranbaxy Unichem Co (RUCL). "The new representative of the proposed integrated entity will be Suthas Thongprasert, who presently heads DSTH," the company said.

Industry